Vall d'Hebron Institute of Oncology (VHIO)
Isabel Puig Borreil, PhD, is a Senior Investigator at Vall d'Hebron Institute of Oncology (VHIO) since September 2009, specializing in Stem Cells and Cancer under the guidance of Principal Investigator Héctor G Palmer, PhD. In addition, Isabel co-founded Oniria Therapeutics in March 2022, serving as a Scientific Advisor focusing on new therapeutic targets. Prior experience includes postdoctoral research at Institut Curie from July 2005 to July 2009, working on the Normal and Pathological Development of Melanocytes under Lionel Larue, PhD, and a PhD student at Instituto Hospital del Mar de Investigaciones Médicas (IMIM) from September 1999 to June 2005, exploring mechanisms of tumorigenesis under Antonio García de Herreros, PhD. Isabel holds a PhD in Health and Life Sciences from Universitat Pompeu Fabra (2005) and a Master's degree in the same field from the same institution (2002), as well as a Bachelor's degree in Biology with a specialization in Biomedicine from Universitat de Barcelona (2000).
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.